Flumonertinib after prior third-generation EGFR-tyrosine kinase inhibitor (TKI) therapy in patients with epidermal growth factor receptor-mutated non-small cell lung cancer after resistance to third-generation tyrosine kinase inhibitor treatment: a real-world study.

J Thorac Dis · 2026 · PMC12875795 · PMID 41660441

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Other factors, including IP, baseline brain metastases, smoking history, and radiotherapy history, did not reach statistical significance, as their P values were greater than 0.05 and their 95% CIs exceeded 1.0.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.